Inclusivity of patients in early phase breast cancer clinical trials☆

被引:0
|
作者
Sinha, A. [1 ]
Barwell, L. [1 ]
Jeffery, H. [1 ,2 ]
Peterson, Z. [1 ,2 ]
Shifa, B. [1 ,2 ]
Attia, M. [2 ,3 ]
Badawy, K. [1 ]
Purushotham, A. [1 ,2 ]
机构
[1] Kings Coll London, London, England
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] Cairo Univ, Fac Med, Dept Gen Surg, Cairo, Egypt
来源
JOURNAL OF CANCER POLICY | 2024年 / 41卷
关键词
Diversity; Clinical Trials; Recruitment; Ethnicity; UNDER-REPRESENTATION; STREPTOMYCIN;
D O I
10.1016/j.jcpo.2024.100494
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Studies have shown that certain groups of patients are underrepresented in clinical trials including non-Caucasian ethnicity, poor fluency in English, low socioeconomic status, older age, neurodivergence, and large Body Mass Index (BMI). There is a need to ensure adequate representation of these groups so that the results of any trial accurately reflect the population. The aim of this study was to review the pathway of patients recruited into two early phase breast cancer clinical and determine the inclusivity of patients from the aforementioned sub-groups. Methods: The Breast Cancer Research Database was reviewed, and the characteristics of all patients who were screened for eligibility in two early phase clinical trials was examined. The English Indices of Deprivation was used to populate the Index of Multiple Deprivation (IMD) for each patient using their postcode. Results: In total, 392 patients were eligible to participate, between September 2020 to May 2023. Of these, 144 (36.7 %) were recruited to these two trials. In all, 100 % of patients eligible for these trials were approached and screened for participation. Eligible patients had a mean age of 53.5 years. Recruited patients were younger on average than those not recruited (49.1 years vs 56.0 years, p<0.0001). Only one recruited patient required an interpreter, compared with 24 (9.7 %%) of those who were not recruited (p<0.001). There was no difference in the IMD (p=0.38), BMI (p=0.34) and neurodiversity (p=0.10) between patients recruited into clinical trials and those who were not. Conclusion: Older age and poor fluency in the English language remain barriers to participation in early-phase clinical trials despite implementing a clear pathway to trial recruitment. There is a pressing need to address these barriers by raising awareness, improve appropriate training and providing comprehensive trial information to patients in the language of their choice.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] EVOLUTION AND LANDSCAPE OF CLINICAL TRIALS FOR BREAST CANCER PATIENTS
    Dogan, S.
    Goubar, A.
    Arnedos, M.
    Delaloge, S.
    Andre, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [22] Exclusion of Male Patients in Breast Cancer Clinical Trials
    Duma, Narjust
    Hoversten, Katherine P.
    Ruddy, Kathryn J.
    JNCI CANCER SPECTRUM, 2018, 2 (02)
  • [23] Phase II clinical trials with rhizoxin in breast cancer and melanoma
    Hanauske, AR
    Catimel, G
    Aamdal, S
    Huinink, WT
    Paridaens, R
    Pavlidis, N
    Kaye, SB
    teVelde, A
    Wanders, J
    Verweij, J
    BRITISH JOURNAL OF CANCER, 1996, 73 (03) : 397 - 399
  • [24] Pharmaceutical involvement in phase II breast cancer clinical trials
    Schneider, A.
    Zhang, T.
    Kamal, A.
    Patel, K.
    Hamilton, E. P.
    Peppercorn, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Compliance in Early-Phase Cancer Clinical Trials Research
    Kurzrock, Razelle
    Stewart, David J.
    ONCOLOGIST, 2013, 18 (03): : 308 - 313
  • [26] Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer
    Sharma, Alisha
    Searle, Karlee
    Hasan, Salwa
    Chan, Stephanie
    Pond, Gregory
    Jerzak, Katarzyna J.
    CLINICAL BREAST CANCER, 2022, 22 (07) : 629 - 633
  • [27] 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials
    Kilburn, L. S.
    CLINICAL ONCOLOGY, 2008, 20 (01) : 35 - 39
  • [28] Spirituality in cancer patients on phase 1 clinical trials
    Ferrell, Betty
    Chung, Vincent
    Koczywas, Marianna
    Borneman, Tami
    Irish, Terry L.
    Ruel, Nora H.
    Azad, Nilofer S.
    Cooper, Rhonda S.
    Smith, Thomas J.
    PSYCHO-ONCOLOGY, 2020, 29 (06) : 1077 - 1083
  • [29] Patients with metastatic breast cancer enrolled in phase I clinical trials: Clinical outcomes and cohort trends.
    Weiss, Jennifer
    Gao, Dexiang
    Elias, Anthony D.
    Borges, Virginia F.
    Kabos, Peter
    Davis, S. Lindsey
    Leong, Stephen
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Symptom clusters in patients with advanced cancer in an early-phase clinical trials clinic.
    George, Goldy
    Iwuanyanwu, Eucharia Chiege
    Yusuf, Alizeh
    Anderson, Karen O.
    Piha-Paul, Sarina Anne
    Naing, Aung
    Janku, Filip
    Subbiah, Vivek
    Wang, Xin Shelley
    Shi, Qiuling
    Mendoza, Tito R.
    Hong, David S.
    Cleeland, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)